Why Are Idera Pharmaceuticals Shares Soaring Today

  • Idera Pharmaceuticals Inc IDRA shared positive interim results from its investigator-sponsored Phase 2 trial, INTRIM 1, involving tilsotolimod, Idera's synthetic Toll-like receptor 9 agonist. 
  • Based on these results, the trial has been stopped early.
  • The trial included patients with localized, excised melanoma (pathological tumor stage 3-4) with no regional metastases detected and no evidence of distant metastasis. 
  • Noting that there were more patients with ulcerated lesions in the placebo arm than in the tilsotolimod arm, topline interim results showed a 70% lower SLN+ rate among patients injected with tilsotolimod as compared to those injected with placebo.
  • The placebo SLN+ rate was in the mid-40%s. 
  • Related: Idera Shares Fall After Early Tilsotolimod Data, Seeks Collaborating Partners For TLR9 Agonist.
  • Statistical significance exceeded the pre-specified p-value of 0.008. 
  • Adverse reactions included injection site reactions, malaise, fever, and flu-like symptoms.
  • This interim result validates previously reported results from INTRIM 1 that showed immune activation.
  • The trial will continue to relapse-free survival (RFS) and overall survival (OS) at 5 and 10 years after SLN biopsy.
  • Price Action: IDRA shares are up 24.50% at $0.44 on the last check Tuesday.

Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving